申请人:Hoffmann-La Roche Inc.
公开号:US06756380B1
公开(公告)日:2004-06-29
Compounds of the general formula are described:
wherein
R1 is hydrogen or halogen;
R2 is hydrogen, halogen, lower alkyl or lower alkoxy;
R3 is halogen, trifluoromethyl, lower alkoxy or lower alkyl;
R4/R4′are each independently hydrogen or lower alkyl;
R5 is lower alkyl, lower alkoxy, amino, hydroxy, hydroxy-lower alkyl, —(CH2)n-piperazinyl, optionally substituted by lower alkyl, —(CH2)n-morpholinyl, —(CH2)n+1-imidazolyl, —O—(CH2)n+1-morpholinyl, —O—(CH2)n+1-piperidinyl, lower alkyl-sulfanyl, lower alkyl-sulfonyl, benzylamino, —NH—(CH2)n+1N(R4″)2, —(CH2)n—NH—(CH2)n+1N(R4″)2, —(CH2)n+1N(R4″)2, or —O—(CH2)n+1N(R4″)2, wherein R4″ is hydrogen or lower alkyl;
R6 is hydrogen;
R2 and R6 or R1 and R6 may together be —CH═CH—CH═CH—, wherein R2 and R6 or R1 and R6, respectively, together with the two carbon ring atoms to which they are attached form a fused ring, with the proviso that n for R1 is 1;
n is independently 0-2; and
X is —C(O)N(R4″)— or —N(R4″)C(O)—;
and pharmaceutically acceptable acid addition salts thereof.
描述了一般公式的化合物:其中R1是氢或卤素;R2是氢、卤素、低烷基或低烷氧基;R3是卤素、三氟甲基、低烷氧基或低烷基;R4/R4′分别是氢或低烷基;R5是低烷基、低烷氧基、氨基、羟基、羟基-低烷基、—(CH2)n-哌嗪基,可选地被低烷基取代,—(CH2)n-吗啉基,—(CH2)n+1-咪唑基,—O—(CH2)n+1-吗啉基,—O—(CH2)n+1-哌啶基,低烷基硫基,低烷基磺酰基,苄氨基,—NH—(CH2)n+1N(R4″)2,—(CH2)n—NH—(CH2)n+1N(R4″)2,—(CH2)n+1N(R4″)2,或—O—(CH2)n+1N(R4″)2,其中R4″是氢或低烷基;R6是氢;R2和R6或R1和R6可以共同为—CH2CH—CH2CH—,其中R2和R6或R1和R6,分别与它们连接的两个碳环原子形成融合环,但R1的n为1;n独立地为0-2;X为—C(O)N(R4″)—或—N(R4″)C(O)—;以及其药学上可接受的酸盐。